Fabhalta Capsules Specified Drug-use Survey

Novartis

Status: Enrolling

Conditions: C3 Glomerulopathy

Study type: Observational

Funder types: Industry

Identifiers

NCT07156149

CLNP023B11401

Details and patient eligibility

About

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

Enrollment: 50 estimated patients

Sex: All

Ages: Under 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).

Exclusion criteria

• Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

Trial design

50 participants in 1 patient group

iptacopan

Description:

patients administered iptacopan in clinical practice